Pharming Group N.V. today announced it has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in all remaining territories, which includes all remaining EU markets. Under the agreement, the license is being terminated with effect from 1 January 2020 in all 36 countries with a smooth handover planned in the countries where Sobi has sales activities. Pharming will pay Sobi €7.5 million in two tranches.

Pharming Group N.V. presents at the first "PharmingForum" Day on the 26th of October 2019 in Gilze en Rijen. Pharming was honored to present to the forum members alongside our esteemed colleague Professor Michael Osthoff, M.D. from Basel University.

Pharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2019.

CSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao.

Pharming Group N.V. today confirmed it has been included in an injunction in the US obtained by CSL Behring, a subsidiary of CSL Limited of Australia (“CSL”), to prevent possible transmission of proprietary documents and data to Pharming which CSL claims have been removed from its systems by Dr Joseph Chiao, who was hired recently by Pharming to be a medical director.

CEO of Pharming Sijmen de Vries presented at the 21st Annual Global Life Science Investment Conference on the 9th of September in New York City.

Pharming Group N.V. announces it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).

Pharming Group N.V. presents its (unaudited) interim financial report for the first half year ended 30 June 2019.

Pharming Webinar: halfjaarcijfers 2019 donderdag 25 juli 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!

Pharming Group N.V. today announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia